Dependence on the Pyrimidine Biosynthetic Enzyme DHODH Is a Synthetic Lethal Vulnerability in Mutant KRAS-Driven Cancers.

doi:10.1016/j.chembiol.2018.03.005

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Dependence on the Pyrimidine Biosynthetic Enzyme DHODH Is a Synthetic Lethal Vulnerability in Mutant KRAS-Driven Cancers.

Cell chemical biology - 21 Jun 2018

Koundinya Malvika, Sudhalter Judith, Courjaud Albane, Lionne Bruno, Touyer Gaetan, Bonnet Luc, Menguy Isabelle, Schreiber Isabelle, Perrault Christelle, Vougier Stephanie, Benhamou Brigitte, Zhang Bailin, He Timothy, Gao Qiang, Gee Patricia, Simard Daniel, Castaldi M Paola, Tomlinson Ronald, Reiling Stephan, Barrague Matthieu, Newcombe Richard, Cao Hui, Wang Yanjun, Sun Fangxian, Murtie Joshua, Munson Mark, Yang Eric, Harper David, Bouaboula Monsif, Pollard Jack, Grepin Claudine, Garcia-Echeverria Carlos, Cheng Hong, Adrian Francisco, Winter Christopher, Licht Stuart, Cornella-Taracido Ivan, Arrebola Rosalia, Morris Aaron

Abstract excerpt

Activating KRAS mutations are major oncogenic drivers in multiple tumor types. Synthetic lethal screens have previously been used to identify targets critical for the survival of KRAS mutant cells, but their application to drug discovery has proven challenging, possibly due in part to a failure of monolayer cultures to model tumor biology. Here, we report the results of a high-throughput synthetic lethal screen...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Screening Assays, Antitumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enzyme Inhibitors

Share to Mice, SCID

Share to Neoplasms, Experimental

Share to Oxidoreductases Acting on CH-CH Group Donors

Share to Pancreatic Neoplasms

Share to Pyrimidines

Share to Small Molecule Libraries

Source

Open in PubMed

Identifiers

PMID: 29628435
DOI: 10.1016/j.chembiol.2018.03.005

Genes

KRAS
DHODH

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dependence on the Pyrimidine Biosynthetic Enzyme DHODH Is a Synthetic Lethal Vulnerability in Mutant KRAS-Driven Cancers.PMID 29628435Read ↗

Changes in the Transcriptome and Synthetic Lethal Dependencies Following <i>KRAS</i> Mutant Expression Reveal Profound Tissue-SpecificitySemantic proximity Read ↗

De novo pyrimidine biosynthesis inhibition synergizes with BCL-X <sub>L</sub> targeting in pancreatic cancerSemantic proximity Read ↗

De novo pyrimidine biosynthesis inhibition synergizes with BCL-XL targeting in pancreatic cancerSemantic proximity Read ↗

Targeting both the enzymatic and non-enzymatic functions of DHODH as a therapeutic vulnerability in c-Myc-driven cancerSemantic proximity Read ↗

Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies.Semantic proximity Read ↗

Identification of DHODH as a therapeutic target in small cell lung cancerSemantic proximity Read ↗

DHODH is an independent prognostic marker and potent therapeutic target in neuroblastomaSemantic proximity Read ↗

Metabolic synthetic lethality by targeting NOP56 and mTOR in KRAS-mutant lung cancer.Semantic proximity Read ↗

Genome-Wide CRISPR Screen for Essential Cell Growth Mediators in Mutant KRAS Colorectal Cancers.Semantic proximity Read ↗

USP39 Deubiquitinase Is Essential for KRAS Oncogene-driven Cancer.Semantic proximity Read ↗

DHODH is an independent prognostic marker and potent therapeutic target in neuroblastomaSemantic proximity Read ↗

A novel three-dimensional high-throughput screening approach identifies inducers of a mutant KRAS selective lethal phenotype.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.